Chi Jie, Li Yaowen, Zhang Na, Liu Huiping, Chen Zhifeng, Li Jiabin, Huang Xiaohui
Department of Pharmacy, Tongling Municipal Hospital, Tongling, Anhui, People's Republic of China.
Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, People's Republic of China.
Infect Drug Resist. 2023 Dec 19;16:7707-7719. doi: 10.2147/IDR.S428485. eCollection 2023.
We explored the inhibition ability of linezolid/fosfomycin combination against biofilms of vancomycin-resistant (VRE) and tried to provide a theoretical basis for the treatment of VRE biofilm-associated infections.
Four clinical isolates of VRE (No.2, No.4, No.5, and No.6) were used for this study, which were collected from the First Affiliated Hospital of Anhui Medical University. The checkerboard method was used to assess the synergistic effect of linezolid and fosfomycin. The inhibition ability of biofilm biomass was evaluated by crystal violet staining, and the metabolic activity was tested by an Alamar blue cell viability assay. Changes in biofilm formation-related genes of the strains after incubating with drugs were investigated via the quantitative real-time polymerase chain reaction (RT-qPCR).
The fractional inhibitory concentration index (FICI) showed that linezolid combined with fosfomycin had a synergistic effect on all four VRE isolates. Compared with linezolid monotherapy, linezolid combined with fosfomycin led to a significant decrease in biofilm biomass and metabolic activity, especially in the mature biofilm. The results of RT-qPCR showed linezolid combined with fosfomycin inhibition biofilm formation through the inhibition of , and transcription in VRE in the initial and mature stages. To the mature biofilm, the combination also reduced the expression of , and .
The combination of linezolid and fosfomycin represented stronger inhibitory effect on the biofilm formation of VRE than linezolid alone.
探讨利奈唑胺/磷霉素联合用药对耐万古霉素肠球菌(VRE)生物膜的抑制能力,为治疗VRE生物膜相关感染提供理论依据。
本研究使用了从安徽医科大学第一附属医院收集的4株VRE临床分离株(2号、4号、5号和6号)。采用棋盘法评估利奈唑胺和磷霉素的协同作用。通过结晶紫染色评估生物膜生物量的抑制能力,通过阿拉玛蓝细胞活力测定法检测代谢活性。通过定量实时聚合酶链反应(RT-qPCR)研究菌株与药物孵育后生物膜形成相关基因的变化。
部分抑菌浓度指数(FICI)表明,利奈唑胺联合磷霉素对所有4株VRE分离株均有协同作用。与利奈唑胺单药治疗相比,利奈唑胺联合磷霉素可显著降低生物膜生物量和代谢活性,尤其是在成熟生物膜中。RT-qPCR结果显示,利奈唑胺联合磷霉素通过抑制VRE在初始和成熟阶段的、和转录来抑制生物膜形成。对于成熟生物膜,联合用药还降低了、和 的表达。
利奈唑胺与磷霉素联合使用对VRE生物膜形成的抑制作用比利奈唑胺单独使用更强。